CFB and melanoma: The complement component (C7), complement factor B (CFB), and A1BG showed a significant increased expression in patients with stage IV melanoma (P = 0.0070, P = 0.0107, P = 0.0371, respectively) and nonresponding patients with a recurrence (P = 0.0302, P = 0.0400, P = 0.0208, respectively).